Drugs.com - Monthly Update January 2026

In our latest episode, we cover the latest approval of Darzalex Faspro for multiple myeloma, age-related near vision loss, and a rare genetic disorder affecting children. We also discuss an extension to the use of Nexplanon, a long-acting birth control, and a simpler transition for those moving from injected to inhaled insulin.Darzalex Faspro (daratumumab and hyaluronidase-fihj) a new approval for use in combination with standard treatments for adults with newly diagnosed multiple myeloma.Yuvezzi (carbachol and brimonidine tartrate), a novel combination eye drop for presbyopia.Zycubo (copper histidinate), the first treatment for Menkes disease in children.Nexplanon (etonogestrel), a birth control implant with an extension of use for up to five years.Afrezza (insulin human), an inhaled insulin, with updated dosing guidance.Chapters(00:00) - Intro (00:21) - Overview (00:47) - Darzalex (02:13) - Yuvezzi (03:06) - Zycubo (03:50) - Nexplanon (04:35) - Afrezza (05:09) - Outro Follow Drugs.com:X, Facebook, YoutubeSignup to our newslettersDownload the app